Story perspectives

OrsoBio's TLC-2716 Shows Promising Phase 1 Results

1/17/2026

33 3

Summary

Story summary

OrsoBio, Inc. announced Phase 1 data for TLC-2716, an oral Liver X Receptor inverse agonist, from a study in 100 healthy volunteers that showed significant triglyceride reductions and up to 61% remnant cholesterol decreases.
The drug showed good tolerability with no serious adverse events reported.
The program targets hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease (MASLD).
A Phase 2a study is underway, with topline results expected in early 2026.

1 of 1

Story summary

OrsoBio, Inc. announced Phase 1 data for TLC-2716, an oral Liver X Receptor inverse agonist, from a study in 100 healthy volunteers that showed significant triglyceride reductions and up to 61% remnant cholesterol decreases.
The drug showed good tolerability with no serious adverse events reported.
The program targets hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease (MASLD).
A Phase 2a study is underway, with topline results expected in early 2026.